Evidence map›Paper›PMID 29416788›Full record

ArticleOncotarget2018

Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer.

Yuzhu Hu, Ting Yu, Xiaoxiao Liu, Yihong He, Lihong Deng, Jiajuan Guo, Yuanqi Hua, Ting Luo, Xiang Gao

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yuzhu HuDepartment of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China.
Ting YuDepartment of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China.
Xiaoxiao LiuDepartment of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China.
Yihong HeDepartment of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China.
Lihong DengDepartment of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China.
Jiajuan GuoDepartment of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China.
Yuanqi HuaDepartment of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China.
Ting LuoDepartment of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China.
Xiang GaoDepartment of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China.
State Key Laboratory of BiotherapySichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is very common worldwide and advanced colorectal cancer exhibited very poor clinical outcome. Oxaliplatin (OXP) is one of the principal chemotherapeutic agents in colorectal cancer treatment presenting impressive anti-tumor ability, limited by adverse effect in clinical practice. Fibrin glue (FG) is a biocompatible formulation made of fibrinogen and thrombin, extensively used in surgery for hemostasis, tissue adhesion and sealing. In this study, FG was innovatively applied as OXP delivery system and results showed enhanced anti-tumor performance in subcutaneous model and abdominal metastasis model of murine colorectal cancer compared with that of OXP used alone. It is revealed that combination of OXP and FG could increase activated CD8

Indexed as

anti-tumor activitycell proliferationcolorectal cancerfibrin glueoxaliplatin

Identifiers

PMID29416788
PMCPMC5788656
OpenAlexW2778190652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.